PROSPECT: This is an observational study and is designed to describe the clinical outcomes and the burden of disease in PD patients with motor fluctuations not adequately controlled by current PD medications.
This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois. AD patients and their caregivers who are living in private homes will be recruited. Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13 The patient and caregiver dyad is required.
I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior. Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.
MOVR: Data Hub is the first and only data hub that aggregates clinical, genetic, and patient reported data for multiple nuromuscular diseases. Collection of patient data about disease progression in the era of new treatments will inform and accelerate future innovation. The combination of data collected through MOVR Data Hub will provide a comprehensive understanding of health and patient experiences in a single data repository. MOVR Data Hub has the power to transform health outcomes, accelerate drug development and drive clinical research across multiple neuromuscular diseases, helpin
NXDC-MEN-301: Subjects are being asked to participate in this study because they have a brain tumor, a meningioma, and surgery is recommended to remove it. The sponsor of this clinical trial, NX Development Corp, has developed the study drug, Gleolan, an imaging agent that in some brain tumors, can make the tumors glow red-violet under a special blue light. This may make it easier for the study surgeon to identify the tumor and to remove it. As part of the study, subjects will drink the Gleolan before your surgery. The goal is to safely remove the tumor.
PADOVA: The purpose of this study is to find out what effects, good and/or bad, prasinezumab versus placebo has on Parkinson’s disease in people who are taking standard medication to manage the disease symptoms.
Lauriet: The purpose of this study is to compare the effects, good or bad, of MTAU9937A versus placebo on patients with moderate AD. In this study, you will get either MTAU9937A or placebo. MTAU9937A is an experimental drug, which means health authorities such as the Food and Drug Administration (FDA) have not approved it for the treatment of moderate AD or other conditions. MTAU9937A is in early development and has been previously studied in healthy subjects and people with milder forms of Alzheimer’s disease.